|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Invested assets: | ||||||||||||||||||||
| Fixed maturity securities, available-for-sale, at fair value (amortized cost: 2026 – $1,496,081; 2025 – $1,448,750) | ||||||||||||||||||||
| Equity securities, at fair value (cost: 2026 – $68,494; 2025 – $66,916) | ||||||||||||||||||||
| Bank loan participations, at fair value | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Other invested assets | ||||||||||||||||||||
| Total invested assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums receivable and agents’ balances, net | ||||||||||||||||||||
| Reinsurance recoverable on unpaid losses, net | ||||||||||||||||||||
| Reinsurance recoverable on paid losses | ||||||||||||||||||||
| Prepaid reinsurance premiums | ||||||||||||||||||||
| Deferred policy acquisition costs | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Income taxes receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held-for-sale (Note 2 - discontinued operations) | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Reserve for losses and loss adjustment expenses | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Payables to reinsurers | ||||||||||||||||||||
| Funds held | ||||||||||||||||||||
| Deferred reinsurance gain | ||||||||||||||||||||
| Senior debt | ||||||||||||||||||||
| Junior subordinated debt | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Liabilities held-for-sale (Note 2 - discontinued operations) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series A redeemable preferred shares – 2026 and 2025: 165,000 shares authorized; 112,500 shares issued and outstanding | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common stock – 2026 and 2025: $0.0002 par value; 200,000,000 shares authorized; 46,239,030 and 45,968,584 shares issued and outstanding, respectively | ||||||||||||||||||||
| Preferred stock – 2026 and 2025: $0.00125 par value; 19,835,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities, Series A redeemable preferred shares, and shareholders’ equity | ||||||||||||||||||||
Loading...
